Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

BACKGROUND: Clinical trials for treatments indicated for orphan diseases may be limited due to the low prevalence of such diseases; this can result in implications for both regulatory and health economic perspectives. This study assessed the pivotal clinical evidence packages submitted to support ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Winstone, Julie, Chadda, Shkun, Ralston, Stephen, Sajosi, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625856/
https://www.ncbi.nlm.nih.gov/pubmed/26511061
http://dx.doi.org/10.1186/s13023-015-0349-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625856/
https://www.ncbi.nlm.nih.gov/pubmed/26511061
http://dx.doi.org/10.1186/s13023-015-0349-z

Ejemplares similares